Navigation Links
Researchers report potential new treatment to stop Alzheimer's disease
Date:11/15/2012

Last March, researchers at UCLA reported the development of a molecular compound called CLR01 that prevented toxic proteins associated with Parkinson's disease from binding together and killing the brain's neurons.

Building on those findings, they have now turned their attention to Alzheimer's disease, which is thought to be caused by a similar toxic aggregation or clumping, but with different proteins, especially amyloid-beta and tau.

And what they've found is encouraging. Using the same compound, which they've dubbed a "molecular tweezer," in a living mouse model of Alzheimer's, the researchers demonstrated for the first time that the compound safely crossed the bloodbrain barrier, cleared the existing amyloid-beta and tau aggregates, and also proved to be protective to the neurons' synapses another target of the disease which allow cells to communicate with one another.

The report appears in the current online edition of the journal Brain.

"This is the first demonstration that molecular tweezers work in a mammalian animal model," said Gal Bitan, an associate professor of neurology at UCLA and the senior author of the study. "Importantly, no signs of toxicity were observed in the treated mice. The efficacy and toxicity results support the mechanism of this molecular tweezer and suggest these are promising compounds for developing disease-modifying therapies for Alzheimer's disease, Parkinson's and other disorders."

Molecular tweezers are complex molecular compounds capable of binding to other proteins. Shaped like the letter "C," these compounds wrap around chains of lysine, a basic amino acid that is a constituent of most proteins. Bitan and his colleagues, including Aida Attar, first author of the study and a graduate student in Bitan's lab, have been working with a particular molecular tweezer called CLR01.

In collaboration with scientists at the Universit Cattolica in Rome, the researchers, working first in cell cultures, found that CLR01 effectively inhibited a process known as synaptotoxicity, in which clumps of toxic amyloid damage or destroy a neuron's synapses.

Even though synapses in transgenic mice with Alzheimer's may shut down and the mice may lose their memory, upon treatment, they form new synapses and regain their learning and memory abilities.

"For humans, unfortunately, the situation is more problematic because the neurons gradually die in Alzheimer's disease," Bitan said. "That's why we must start treating as early as possible. The good news is that the molecular tweezers appear to have a high safety margin, so they may be suitable for prophylactic treatment starting long before the onset of the disease."

Next, using a radioactive "label," the researchers were able to confirm that the compound had crossed the mouse's bloodbrain barrier and was effective in clearing the brain of amyloid-beta and tau aggregates.

"This work shows that molecular tweezers do a number of things they help to ameliorate multiple pathologic features of Alzheimer's, including amyloid plaques, neurofibrillary tangles and brain inflammation, and our cell culture experiments demonstrated that molecular tweezers block the toxic effect of amyloid-beta on synaptic integrity and communication," Bitan said.

"We call these unique tweezers 'process-specific,' rather than the common protein-specific inhibitors," he added, meaning the compound only attacks the targeted toxic aggregates and not normal body processes. "That's a big deal, because it helps confirm evidence that the molecular tweezers can be used safely, ultimately supporting their development as a therapy for humans."

The next step, Bitan hopes, is to confirm that the tweezers improve memory and not just brain pathology. The researchers say they are working on this question and already have encouraging preliminary data.


'/>"/>

Contact: Mark Wheeler
mwheeler@mednet.ucla.edu
310-794-2265
University of California - Los Angeles
Source:Eurekalert

Related medicine news :

1. Feinstein Institute researchers discover plant derivative
2. Sociology, economics researchers receive grant to study development across the human lifespan
3. Genital Injuries Common But Preventable, Researchers Say
4. Researchers identify impact of rheumatoid arthritis and lupus on joint replacement surgery outcomes
5. Moffitt Cancer Center researchers identify novel metabolic programs driving aggressive brain tumors
6. Researchers find why nicotine in cigarettes may relieve anxiety in smokers
7. Researchers develop non-invasive technique for predicting patients response to chemotherapy
8. Researchers explore connection between popular pain relievers, bladder cancer
9. Researchers discover immune pathway
10. Temple researchers show targeted cancer drug may stunt hearts ability to repair itself
11. Researchers discover how underground rodent wards off cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... ... and financial planning services to families and business owners in northern Florida, is ... promises to provide support to area adults with developmental challenges. , The First ...
(Date:7/21/2017)... Grove, Ill. (PRWEB) , ... July 21, 2017 , ... ... & Fabric Liquid eco-friendly odor-control solution for colleges and universities at the ... safely and effectively eliminate severe cannabis and tobacco smoke odors without the use of ...
(Date:7/21/2017)... TORONTO, ONTARIO, CANADA (PRWEB) , ... July 21, 2017 , ... ... Chicago, IL and Past President of the American Orthopaedic Society of Sports Medicine ... July 21, 2017 during the AOSSM Annual Meeting in Toronto, Canada. This prestigious award ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... ... has received a $5,000 grant from the C. R. Bard Foundation, Inc. ... Center at Somerset Hills , a service available through the nonprofit home care ...
(Date:7/21/2017)... ... 21, 2017 , ... Sharon Kleyne is proud of the ... research center at Bio-Logic Aqua Research® Water Life Science®, has been released in ... sufferers of blindness. “We think that Nature’s Tears® EyeMist® will contribute to eliminating ...
Breaking Medicine News(10 mins):
(Date:7/20/2017)... July 20, 2017  Prime Therapeutics LLC (Prime) released this ... M.D., following today,s Institute for Clinical and Economic Review,s (ICER) ... the effectiveness and value of abuse-deterrent formulations (ADF) of opioids. ... roundtable at the meeting. ... cost benefit to the use of abuse-deterrent formulations (ADF) in ...
(Date:7/17/2017)... Fla. , July 17, 2017  MedX Holdings, ... branded medical testing, strengthening and rehabilitation equipment, today announced ... Machine Program. MedX is considered the gold standard for ... leader in specialized medical strengthening equipment. ... a lease with the physician or practice who prescribe ...
(Date:7/14/2017)... DUBLIN , July 14, 2017 Endo International plc ... results on Tuesday, August 8, 2017.  Members of its senior management ... financial markets open at 8:30 a.m. ET. The ... (866) 497-0462, International (678) 509-7598, and the passcode is 45397076. ... A replay of the ...
Breaking Medicine Technology: